Garon-Czmil, Julie
Petitpain, Nadine
Rouby, Franck
Sassier, Marion
Babai, Samy
Yéléhé-Okouma, Mélissa
Weryha, Georges
Klein, Marc
Gillet, Pierre http://orcid.org/0000-0002-0598-7508
Funding for this research was provided by:
GW consulted for Novartis and Theramex and received punctual compensations.
Article History
Received: 17 July 2019
Accepted: 30 November 2019
First Online: 19 December 2019
Competing interests
: J.G.C., N.P., F.R., M.S., S.B., M.Y.O., M.K. and P.G. declare no financial competing interests. GW consulted for Novartis and Theramex and received punctual compensations. Nadine PETITPAIN: unpaid membership as expert of the French Drug Agency (ANSM), Unpaid member of the coordination committee of an academic interventional clinical trial (NCT02250729) funded by a consortium of 15 companies marketing pholcodine containing drugs (Bouchara-Recordati, Hepatoum, Biocodex/Leurquin, Pierre Fabre, Sanofi, Urgo, Zambon, Alliance, Bells healthcare, Boots, Ernest Jackson, GSK, Medgenix, Pinewood, Vemedia). Franck ROUBY: unpaid membership as expert of the French Drug Agency (ANSM), unpaid expert (Co-investigator) for clinical Trials (Biogen, Theranexus, Inflectis Bioscience, Roche Genentech, Abbvie, Roche). Marion SASSIER: unpaid membership as expert of the French Drug Agency (ANSM), Samy BABAI: unpaid membership as expert of the French Drug Agency (ANSM), unpaid expert in a multicentric academic study on tranexamic acid. Mélissa YELEHE-OKOUMA: unpaid membership as expert of the French Drug Agency (ANSM), Pierre GILLET: unpaid membership as expert of the French Drug Agency (ANSM), Unpaid member of the coordination committee of an academic interventional clinical trial (NCT02250729) funded by a consortium of 15 companies marketing pholcodine containing drugs (Bouchara-Recordati, Hepatoum, Biocodex/Leurquin, Pierre Fabre, Sanofi, Urgo, Zambon, Alliance, Bells healthcare, Boots, Ernest Jackson, GSK, Medgenix, Pinewood, Vemedia).